消癌平注射液对宫颈癌化疗患者减毒增效作用
|
摘要
目的探讨分析消癌平注射液对宫颈癌化疗患者减毒增效作用。方法 60例宫颈癌患者作为研究对象,随机分为对照组和治疗组,每组30例。对照组采用单纯化疗,治疗组在化疗基础上加用消癌平注射液静脉滴注治疗。化疗2个周期后,比较两组患者的治疗效果、不良反应发生情况及化疗前后生存质量评分。结果治疗组的疾病控制率(DCR)为70.00%(21/30),明显高于对照组的33.33%(10/30),差异有统计学意义(χ2=8.076, P=0.005<0.05)。治疗组化疗后的不良反应发生率为16.67%(5/30),明显低于对照组的53.33%(16/30),差异有统计学意义(χ2=8.864, P=0.003<0.05)。化疗前,两组患者的躯体功能、认知功能、社会功能、角色功能、情绪功能及总体健康评分比较差异均无统计学意义(P>0.05)。化疗后,治疗组的躯体功能、角色功能、总体健康评分均明显优于化疗前,且上述指标均明显优于对照组,差异均有统计学意义(P<0.05)。结论消癌平注射液对宫颈癌化疗患者具有显著的减毒增效作用,可显著改善患者的生存质量,减少不良反应的发生,安全性较高,值得在临床推广使用。
Objective To discuss and analyze the attenuation and synergistic effect of Xiaoaiping injection on chemotherapy patients with cervical cancer. Methods A total of 60 patients with cervical cancer as study subjects were randomly divided into control group and treatment group, with 30 cases in each group. The control group received simple chemotherapy, and the treatment group received intravenous drip of Xiaoaiping injection on the basis of chemotherapy. After 2 weeks of chemotherapy, comparison were made on treatmenteffect, occurrence of adverse reactions and quality of life score before and after chemotherapy between the two groups. Results After treatment, the treatment group had obviously higher disease control rate(DCR) as 70.00%(21/30) than 33.33%(10/30) in the control group, and the difference was statistically significant(χ2=8.076, P=0.005<0.05). The treatment group had obviously lower incidence of adverse reactions as 16.67%(5/30) after chemotherapy than 53.33%(16/30) in the control group, and the difference was statistically significant(χ2=8.864, P=0.003<0.05). Before chemotherapy, both groups had no statistically significant difference in physical function, cognitive function, social function, role function, emotional function and general health score(P>0.05). After chemotherapy, the treatment group had obviously better physical function, role function and general health score than those before chemotherapy and the control group, and their difference was statistically significant(P<0.05). Conclusion Xiaoaiping injection shows significant attenuating and synergistic effect on chemotherapy patients with cervical cancer, and it can significantly improve the quality of life of patients, reduce the occurrence of adverse reactions with high safety. It is worthy of clinical promotion and application.
Objective To discuss and analyze the attenuation and synergistic effect of Xiaoaiping injection on chemotherapy patients with cervical cancer. Methods A total of 60 patients with cervical cancer as study subjects were randomly divided into control group and treatment group, with 30 cases in each group. The control group received simple chemotherapy, and the treatment group received intravenous drip of Xiaoaiping injection on the basis of chemotherapy. After 2 weeks of chemotherapy, comparison were made on treatmenteffect, occurrence of adverse reactions and quality of life score before and after chemotherapy between the two groups. Results After treatment, the treatment group had obviously higher disease control rate(DCR) as 70.00%(21/30) than 33.33%(10/30) in the control group, and the difference was statistically significant(χ2=8.076, P=0.005<0.05). The treatment group had obviously lower incidence of adverse reactions as 16.67%(5/30) after chemotherapy than 53.33%(16/30) in the control group, and the difference was statistically significant(χ2=8.864, P=0.003<0.05). Before chemotherapy, both groups had no statistically significant difference in physical function, cognitive function, social function, role function, emotional function and general health score(P>0.05). After chemotherapy, the treatment group had obviously better physical function, role function and general health score than those before chemotherapy and the control group, and their difference was statistically significant(P<0.05). Conclusion Xiaoaiping injection shows significant attenuating and synergistic effect on chemotherapy patients with cervical cancer, and it can significantly improve the quality of life of patients, reduce the occurrence of adverse reactions with high safety. It is worthy of clinical promotion and application.
引文
[1]Wang XS, Hao XS, Wang Y, et al. Validation study of the Chinese version of the brief fatigue inventory(BFI-C). J Pain Symptom Manage, 2004, 27(4):322-332.
[2]万崇华,陈明清,张灿珍,等.癌症患者生命质量测定量表EORTCQLQ-C30中文版评介.实用肿瘤杂志, 2005, 20(4):353-355.
[3]Donovan KA, Jacobsen PB, Andrykowski MA, et al. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. Pain Symptom Manage, 2004, 28(4):373-380.
[4]李鹤飞,孙振卿,李亚静,等.化疗联合消癌平注射液治疗晚期食管癌的临床观察.北方药学, 2015, 12(5):110.
[5]王树庚,冯亮飞,李丹.消癌平注射液联合化疗治疗非霍奇金淋巴瘤131例.河南中医, 2017, 37(8):1488-1490.
[6]陶小鑫,于浩,柏建岭.消癌平注射液联合化学治疗对非小细胞肺癌的临床疗效及安全性Meta分析.医药导报, 2014,33(1):48-53.
[7]郑振东,王沈玉,宋娜莎.消癌平注射液联合多西他赛+奥沙利铂二线治疗晚期胃癌的有效性和安全性临床研究.中国医院药学杂志, 2017, 37(22):2292-2295.
[8]王新杰,赵明星,杨晓,等.消癌平联合TP方案治疗晚期食管癌疗效观察.现代中西医结合杂志, 2015, 24(33):3699-3701.
[9]刘宏伟,于珊虹,刘凤林,等.消癌平注射液联合化疗治疗晚期食管癌的临床观察.当代医学, 2013(24):3-4.
[10]沙士义.消癌平注射液配合化疗治疗晚期食管癌的增效减毒和改善生活质量的效果.中国现代医生, 2016, 54(33):75-77.
[2]万崇华,陈明清,张灿珍,等.癌症患者生命质量测定量表EORTCQLQ-C30中文版评介.实用肿瘤杂志, 2005, 20(4):353-355.
[3]Donovan KA, Jacobsen PB, Andrykowski MA, et al. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. Pain Symptom Manage, 2004, 28(4):373-380.
[4]李鹤飞,孙振卿,李亚静,等.化疗联合消癌平注射液治疗晚期食管癌的临床观察.北方药学, 2015, 12(5):110.
[5]王树庚,冯亮飞,李丹.消癌平注射液联合化疗治疗非霍奇金淋巴瘤131例.河南中医, 2017, 37(8):1488-1490.
[6]陶小鑫,于浩,柏建岭.消癌平注射液联合化学治疗对非小细胞肺癌的临床疗效及安全性Meta分析.医药导报, 2014,33(1):48-53.
[7]郑振东,王沈玉,宋娜莎.消癌平注射液联合多西他赛+奥沙利铂二线治疗晚期胃癌的有效性和安全性临床研究.中国医院药学杂志, 2017, 37(22):2292-2295.
[8]王新杰,赵明星,杨晓,等.消癌平联合TP方案治疗晚期食管癌疗效观察.现代中西医结合杂志, 2015, 24(33):3699-3701.
[9]刘宏伟,于珊虹,刘凤林,等.消癌平注射液联合化疗治疗晚期食管癌的临床观察.当代医学, 2013(24):3-4.
[10]沙士义.消癌平注射液配合化疗治疗晚期食管癌的增效减毒和改善生活质量的效果.中国现代医生, 2016, 54(33):75-77.